126 related articles for article (PubMed ID: 37259686)
21. Treating lymphoma is now a bit EZ-er.
Morin RD; Arthur SE; Assouline S
Blood Adv; 2021 Apr; 5(8):2256-2263. PubMed ID: 33904892
[TBL] [Abstract][Full Text] [Related]
22. EZH2 and CD79B mutational status over time in B-cell non-Hodgkin lymphomas detected by high-throughput sequencing using minimal samples.
Saieg MA; Geddie WR; Boerner SL; Bailey D; Crump M; da Cunha Santos G
Cancer Cytopathol; 2013 Jul; 121(7):377-86. PubMed ID: 23361872
[TBL] [Abstract][Full Text] [Related]
23. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.
Pastore A; Jurinovic V; Kridel R; Hoster E; Staiger AM; Szczepanowski M; Pott C; Kopp N; Murakami M; Horn H; Leich E; Moccia AA; Mottok A; Sunkavalli A; Van Hummelen P; Ducar M; Ennishi D; Shulha HP; Hother C; Connors JM; Sehn LH; Dreyling M; Neuberg D; Möller P; Feller AC; Hansmann ML; Stein H; Rosenwald A; Ott G; Klapper W; Unterhalt M; Hiddemann W; Gascoyne RD; Weinstock DM; Weigert O
Lancet Oncol; 2015 Sep; 16(9):1111-1122. PubMed ID: 26256760
[TBL] [Abstract][Full Text] [Related]
24. Genetic and epigenetic inactivation of
Oricchio E; Katanayeva N; Donaldson MC; Sungalee S; Pasion JP; Béguelin W; Battistello E; Sanghvi VR; Jiang M; Jiang Y; Teater M; Parmigiani A; Budanov AV; Chan FC; Shah SP; Kridel R; Melnick AM; Ciriello G; Wendel HG
Sci Transl Med; 2017 Jun; 9(396):. PubMed ID: 28659443
[TBL] [Abstract][Full Text] [Related]
25. Identification of Recurrent Mutations in the microRNA-Binding Sites of B-Cell Lymphoma-Associated Genes in Follicular Lymphoma.
Larrea E; Fernandez-Mercado M; Guerra-Assunção JA; Wang J; Goicoechea I; Gaafar A; Ceberio I; Lobo C; Okosun J; Enright AJ; Fitzgibbon J; Lawrie CH
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233721
[TBL] [Abstract][Full Text] [Related]
26. Follicular lymphoma, a B cell malignancy addicted to epigenetic mutations.
Korfi K; Ali S; Heward JA; Fitzgibbon J
Epigenetics; 2017 May; 12(5):370-377. PubMed ID: 28106467
[TBL] [Abstract][Full Text] [Related]
27. Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response.
Béguelin W; Teater M; Meydan C; Hoehn KB; Phillip JM; Soshnev AA; Venturutti L; Rivas MA; Calvo-Fernández MT; Gutierrez J; Camarillo JM; Takata K; Tarte K; Kelleher NL; Steidl C; Mason CE; Elemento O; Allis CD; Kleinstein SH; Melnick AM
Cancer Cell; 2020 May; 37(5):655-673.e11. PubMed ID: 32396861
[TBL] [Abstract][Full Text] [Related]
28. FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy.
Mottok A; Jurinovic V; Farinha P; Rosenwald A; Leich E; Ott G; Horn H; Klapper W; Boesl M; Hiddemann W; Steidl C; Connors JM; Sehn LH; Gascoyne RD; Hoster E; Weigert O; Kridel R
Blood; 2018 Jan; 131(2):226-235. PubMed ID: 29122756
[TBL] [Abstract][Full Text] [Related]
29. EZH2 Y641 mutations in follicular lymphoma.
Bödör C; O'Riain C; Wrench D; Matthews J; Iyengar S; Tayyib H; Calaminici M; Clear A; Iqbal S; Quentmeier H; Drexler HG; Montoto S; Lister AT; Gribben JG; Matolcsy A; Fitzgibbon J
Leukemia; 2011 Apr; 25(4):726-9. PubMed ID: 21233829
[No Abstract] [Full Text] [Related]
30. A Cohort Study of the Prognostic Impact of Exon-16 EZH2 Mutations in a Mexican-Mestizo Population of Patients with Diffuse Large B-Cell Lymphoma.
Oñate-Ocaña LF; Ponce-Martínez M; Taja-Chayeb L; Gutiérrez-Hernández O; Avilés-Salas A; Cantú-de-León D; Dueñas-González A; Candelaria-Hernández M
Rev Invest Clin; 2021 Nov; 73(6):362-370. PubMed ID: 34044429
[TBL] [Abstract][Full Text] [Related]
31. Refining the management of relapsed or refractory follicular lymphoma.
Pagel JM; Burke JM; Leslie LA
Clin Adv Hematol Oncol; 2020 Dec; 18 Suppl 20(12):1-24. PubMed ID: 33843893
[TBL] [Abstract][Full Text] [Related]
32. H3K27m3 overexpression as a new, BCL2 independent diagnostic tool in follicular and cutaneous follicle center lymphomas.
Brune MM; Vela V; Bratic Hench I; Dertinger S; Borgmann V; Dirnhofer S; Tzankov A
Virchows Arch; 2022 Sep; 481(3):489-497. PubMed ID: 35661922
[TBL] [Abstract][Full Text] [Related]
33. Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas.
Morschhauser F; Salles G; Batlevi CL; Tilly H; Chaidos A; Phillips T; Burke J; Melnick A
Blood Rev; 2022 Nov; 56():100988. PubMed ID: 35851487
[TBL] [Abstract][Full Text] [Related]
34. EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL.
Brach D; Johnston-Blackwell D; Drew A; Lingaraj T; Motwani V; Warholic NM; Feldman I; Plescia C; Smith JJ; Copeland RA; Keilhack H; Chan-Penebre E; Knutson SK; Ribich SA; Raimondi A; Thomenius MJ
Mol Cancer Ther; 2017 Nov; 16(11):2586-2597. PubMed ID: 28835384
[TBL] [Abstract][Full Text] [Related]
35. EZH2 Expression in Follicular Lymphoma Is Variable and Independent from the Progression of Disease Within 24 Months of First Treatment.
Szumera-CieĆkiewicz A; Poleszczuk J; Paszkiewicz-Kozik E; Rymkiewicz G; SokÓŁ K; Borysiuk A; Kotarska M; Owczarek D; Kawecka M; Pytlak B; Walewski J; Prochorec-Sobieszek M
Anticancer Res; 2020 Dec; 40(12):6685-6697. PubMed ID: 33288562
[TBL] [Abstract][Full Text] [Related]
36. Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay.
Lyu N; Rajendran VK; Diefenbach RJ; Charles K; Clarke SJ; Engel A; ; Rizos H; Molloy MP; Wang Y
Nanotheranostics; 2020; 4(4):224-232. PubMed ID: 32923312
[TBL] [Abstract][Full Text] [Related]
37. EZH2 overexpression in primary gastrointestinal diffuse large B-cell lymphoma and its association with the clinicopathological features.
Liu Y; Yu K; Li M; Zeng K; Wei J; Li X; Liu Y; Zhao D; Fan L; Yu Z; Wang Y; Li Z; Zhang W; Bai Q; Yan Q; Guo Y; Wang Z; Guo S
Hum Pathol; 2017 Jun; 64():213-221. PubMed ID: 28438623
[TBL] [Abstract][Full Text] [Related]
38. Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium.
Stevens WBC; Mendeville M; Redd R; Clear AJ; Bladergroen R; Calaminici M; Rosenwald A; Hoster E; Hiddemann W; Gaulard P; Xerri L; Salles G; Klapper W; Pfreundschuh M; Jack A; Gascoyne RD; Natkunam Y; Advani R; Kimby E; Sander B; Sehn LH; Hagenbeek A; Raemaekers J; Gribben J; Kersten MJ; Ylstra B; Weller E; de Jong D
Haematologica; 2017 Aug; 102(8):1413-1423. PubMed ID: 28411252
[TBL] [Abstract][Full Text] [Related]
39. Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma.
Li H; Kaminski MS; Li Y; Yildiz M; Ouillette P; Jones S; Fox H; Jacobi K; Saiya-Cork K; Bixby D; Lebovic D; Roulston D; Shedden K; Sabel M; Marentette L; Cimmino V; Chang AE; Malek SN
Blood; 2014 Mar; 123(10):1487-98. PubMed ID: 24435047
[TBL] [Abstract][Full Text] [Related]
40. ctDNA Is Useful to Detect Mutations at Codon 641 of Exon 16 of EZH2, a Biomarker for Relapse in Patients with Diffuse Large B-Cell Lymphoma.
Díaz-Chávez J; Gutiérrez-Hernández O; Taja-Chayeb L; Gutiérrez-Chavarría S; Avilés-Salas A; Candelaria M
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]